Starpharma Holdings Limited · ASX:SPL

Starpharma — Investor Presentation (August 2007)

30 slides from Starpharma's investor presentation, Aug 24, 2007

  1. Slide 1: Investor Presentation

    Investor Presentation Melbourne, Australia. Friday 24th August 2007. Dr Jackie Fairley, CEO of For personal use only Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) will be presenting a company update to institutional investors, analysts and brokers today. A copy of the slide presentation is attached

  2. Slide 2: For personal use only

    authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regardi

  3. Slide 3: Corporate Presentation August 2007

    For personal use only Corporate Presentation August 2007 ASX:SPL OTCQX:SPHRY

  4. Slide 4: Forward-looking statements

    For personal use only This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targe

  5. Slide 5: Company Overview

    For personal use only Company Overview ƒ World leader in developing dendrimer products for Starpharma Holdings Limited (8/8/07) pharmaceutical and life-sciences ASX Code SPL Level 1 ADR (OTCQX) SPHRY ƒ Lead product VivaGel™ is being developed (with Share Price SPL AUD 39c >$20M NIH support) under IN

  6. Slide 6: Investment Summary

    For personal use only Investment Summary ƒ Starpharma has a leading topical microbicide (VivaGel™) in development for prevention of sexually transmitted infections (STIs), HIV and genital herpes ƒ Topical microbicides have strong consumer demand and funding support ƒ VivaGel™ will be “first in class

  7. Slide 7: Company Structure

    For personal use only Company Structure 8.6% Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY 100% 100% Dendritic Nanotechnologies Starpharma Pty Ltd Inc. (DNT) ƒ 36 employees based in Melbourne, ƒ Wholly owned subsidiary based in Australia Michigan, USA (16 employees) ƒ Leading developer of dendrime

  8. Slide 8: Shareholding and ADR (SPHRY) Uptake

    For personal use only Shareholding and OTCQX:SPHRY ƒ Major shareholders include: ADR (SPHRY) Uptake ƒ The Dow Chemical Company (NASDQ:DOW) OTCQX : SPHRY ƒ Acorn Capital American Depositary Receipts (ADRs) on issue ƒ Biotech Capital 1 ADR = 10 SPL shares 2,000,000 1,800,000 ƒ Queensland Investment Co

  9. Slide 9: Technology Overview

    For personal use only Technology Overview Starpharma’s existing Unique Characteristics of Dendrimers: commercial agreements for dendrimers ƒ Precisely defined, synthetic macromolecules (1-10nm) ƒ Can be designed to precisely define surface topology, optimize Stratus CS® : Cardiac marker potency, pha

  10. Slide 10: Technology Overview (continued)

    For personal use only Technology Overview (continued) Commercial Advantages of Dendrimers: ƒ Key enabling nanoscale technology Example: dendrimer as a drug delivery vehicle ƒ Highly versatile technology : ƒ drugs (VivaGel), ƒ drug delivery, ƒ RNAi/DNA delivery, ƒ diagnostics & materials applications

  11. Slide 11: Product Pipeline

    For personal use only Product Pipeline

  12. Slide 12: Starpharma's Pipeline: Balanced for Risk

    For personal use only Starpharma’s Pipeline: Balanced for Risk Pharmaceutical & Medical Products Proof of Concept Lead Clinical Trials Sales VivaGel™ * Genital Herpes prevention * HIV prevention * condom coating & other line extensions ADME Engineering™ * Therapeutic protein PK optimisation Drug Del

  13. Slide 13: VivaGel - Lead Product for Prevention of Sexually Transmitted Infections (STIs)

    For personal use only VivaGelTM - Lead Product for Prevention of Sexually Transmitted Infections (STIs )

  14. Slide 14: VivaGel – Lead Product for Prevention of Sexually Transmitted Infections (STIs)

    For personal use only VivaGelTM – Lead Product for Prevention of Sexually Transmitted Infections (STIs) ƒ VivaGel™ is a topical vaginal microbicide being HIV developed to prevent STIs in women ƒ Major health burden in both ƒ Being developed under two INDs for the prevention of developed and developi

  15. Slide 15: Commercial Opportunity for Microbicides

    For personal use only Commercial Opportunity for Microbicides ƒ Large, addressable markets ¾ HIV more common in developing countries Estimated Market for microbicides in Developed Countries ¾ HSV-2 common in both developing and developed countries Market Average Frequency Penetration of Use Per Annu

  16. Slide 16: VivaGel – Product Features and Performance

    For personal use only VivaGel™ – Product Features and Performance VivaGel™ Offers „ Market research indicates significant (international) user and payor demand for Several Key microbicide gels Advantages „ VivaGel™ : “first in class” for Herpes „ Compelling HSV-2 & HIV efficacy and potent contracept

  17. Slide 17: VivaGel - Clinical Trial Status

    For personal use only VivaGel™ - Clinical Trial Status Study No. Site(s) IND Status Participants Application Safety, tolerability and 37 Adelaide, Prevention of Complete pharmacokinetic study of Australia HIV escalating doses of VivaGel in healthy women when administered vaginally, once daily for 7

  18. Slide 18: VivaGel - Development stage and plan

    For personal use only VivaGel™ - Development stage and plan PRODUCT TYPE Typical In vitro In vivo In vivo Market Therapeutic Phase 1 Phase 2 Phase 3 efficacy efficacy safety entry Agent Preventative Expanded Population In vitro In vivo In vivo Market “Drug” Phase 1 Safety Based entry efficacy effica

  19. Slide 19: The Condom Coating Opportunity

    For personal use only The Condom Coating Opportunity The Reason for the Opportunity VivaGel™ is NOT a surfactant Condom Market at a Glance • Condom manufacturers have long Total Sales: US$3.26B (2006) recognised a demand for premium Illustration of surfactant action Top 4 sales: 70% of total condoms

  20. Slide 20: VivaGel – Development and Commercial Strategy

    For personal use only VivaGelTM – Development and Commercial Strategy ƒ One of the most advanced 2nd generation microbicides for HIV ƒ First in class for HSV-2 ƒ Significant non-dilutive NIH support; strong ongoing support for microbicides ƒ Broad application; chronic-use product VivaGel™ ƒ Partneri

  21. Slide 21: Portfolio: Overview of Opportunities

    For personal use only Portfolio: Overview of Opportunities Multiple Near-Term Future High-Value Commercial Commercial Opportunities Opportunities Pharmaceutical Industrial Products Life-science Applications Applications siRNA, DNA transfection VivaGel™ Industrial Reagents Chemicals Medical Protein D

  22. Slide 22: Portfolio: siRNA Delivery – PrioFect

    For personal use only Portfolio: siRNA Delivery – PrioFect™ Concept: Overcome the principal obstacle to the development of RNAi-based drugs … delivery Commercial opportunities for PrioFect™: “RNAi-based therapies have so far failed to take off because of the 1. Research reagent market($200 million)

  23. Slide 23: Portfolio: siRNA Delivery – PrioFect

    For personal use only Portfolio: siRNA Delivery – PrioFect™ Concept: Overcome the principal obstacle to the development of RNAi-based drugs … delivery Technology Inhibiting Protein Expression Significance Potential for worse Œ Cell specific targeting 100 Œ Enhanced residence time Protein Expression

  24. Slide 24: Portfolio: Drug Optimization or Therapeutic Protein PK modification

    For personal use only Portfolio: Drug Optimization or Therapeutic Protein PK (pharmacokinetic) modification Concept: increase half life of drugs by attaching to dendrimer Technology Extending Drug Half Life Significance Potential for Πless frequent dosing Payload Drug 80 ΠReduced cost of therapy C

  25. Slide 25: Portfolio: Drug Delivery

    For personal use only Portfolio: Drug Delivery Concept: Attach drugs to dendrimers to control and modify distribution Technology Dendrimers can be Targeted Significance Optional Potential for Targeting Payload ΠImproved efficacy of drugs Element Drug ΠReduced off-target effects ΠProduct lifecycle

  26. Slide 26: Portfolio: Industrial Applications

    Portfolio: Industrial Applications For personal use only Sector Current Discussions with… Application Market Size USD /Region Major Reagent manufacturers Fluorescent dye conjugate $100M /US Research Reagents Major Reagent manufacturers Dyes for in vitro diagnostics $2.5B /US Automotive Lubricants "T

  27. Slide 27: Partners and Collaborators

    For personal use only Partners and Collaborators Industry Collaborators Research/ University Collaborators NICHD NIAID 25

  28. Slide 28: Starpharma: 06/07 Highlights

    For personal use only Starpharma: 06/07 Highlights Acquisition of DNT SPL acquires US company DNT Dow becomes SPL’s largest holder Integration of SPL and DNT complete Richard Hazelton appointment Retired Dow Corning Chairman/CEO appointed to SPL Board VivaGel™ clinical trial progress Expanded safety

  29. Slide 29: Key Investment Highlights

    For personal use only Key Investment Highlights ƒ Compelling competitive advantages VivaGel™: A Unique ƒ Clinical candidate with Significant support from NIH (>US$20M) Lead Product ƒ First in class for genital herpes; condom coating line extension ƒ HIV and genital herpes at epidemic proportions Sig

  30. Slide 30: Starpharma Holdings Limited

    For personal use only Starpharma Holdings Limited ASX:SPL OTCQX:SPHRY Dr Jackie Fairley CEO SPL US$M +613 85322704 Market Capitalisation ~55 Further information: NIH Support >26 www.starpharma.com Cash on Hand (Jun 07) 8.5 info@starpharma.com $1 AUD = 0.845 USD

Starpharma Holdings — Investor Presentation (August 2007) on 6ix